{"id":"W4308026783","doi":"10.1136/jitc-2022-005780","title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Juravinski Cancer Centre; Université du Québec à Montréal","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; EMD Serono; Genentech; European Society for Medical Oncology; Shionogi; Natera; Seagen; Pfizer; Incyte; Jounce Therapeutics; Astellas Pharma; Eisai; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; Dana-Farber Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Tolerability; Renal cell carcinoma; Discontinuation; Combination therapy; Hazard ratio; Clinical endpoint; Progression-free survival; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000478919,0.0003534984,0.0007856073,0.0002928544,0.0005689745,0.00002702532,0.0002402459,0.0001288952,0.0012878],"category_scores_gemma":[0.00001328589,0.0002773862,0.0007652726,0.000182433,0.00008410978,0.000138512,0.0000313747,0.0005265323,0.000001900358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002776099,"about_ca_system_score_gemma":0.001094971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005034353,"about_ca_topic_score_gemma":0.000006591273,"domain_scores_codex":[0.9975361,0.0001321648,0.0007713675,0.0003819912,0.0006668594,0.0005114764],"domain_scores_gemma":[0.9979675,0.0002354809,0.0008340382,0.0004285444,0.0004066694,0.000127799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2146422,0.001484397,0.00180159,0.0001255786,0.0006267055,0.00006069792,0.001080921,0.0006995324,0.3618798,0.00001516381,0.003408555,0.4141749],"study_design_scores_gemma":[0.06764539,0.04545395,0.01255881,0.0001887952,0.0002236813,0.0003276401,0.000711343,0.0002212335,0.2891729,0.000360506,0.5826867,0.0004490933],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.945512,0.04812121,0.0004829586,0.001176851,0.001527376,0.002649577,0.0001171612,0.00002723467,0.0003856443],"genre_scores_gemma":[0.984817,0.00291185,0.003421973,0.0009500544,0.0005491144,0.003753738,0.00004704372,0.000135006,0.003414275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5792782,"threshold_uncertainty_score":0.9999678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02410113479203347,"score_gpt":0.3518191333851835,"score_spread":0.32771799859315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}